Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database
Int. Journal of Clinical Pharmacology and Therapeutics · 2023
DOI: 10.5414/cp204372 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2023. Verfasst von Ryo Inose und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Lymphoma, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Inose, R., Nakamura, A., Omi, R., Takeno, S., & Muraki, Y. (2023). Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204372
Vancouver
Inose R, Nakamura A, Omi R, Takeno S, Muraki Y. Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database. Int. Journal of Clinical Pharmacology and Therapeutics. 2023. doi:10.5414/cp204372
BibTeX
@article{Inose2023,
author = {Inose, Ryo and Nakamura, Arisa and Omi, Rina and Takeno, Shujiro and Muraki, Yuichi},
title = {Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2023},
doi = {10.5414/cp204372}
}
EUVIMED